/SILO
SILO Stock - Silo Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$0.38-1.40%
$0.01 (-1.40%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.42
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SILO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.38 – $0.38
TARGET (TP)$0.44
STOP LOSS$0.35
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.64
52W High$3.37
52W Low$0.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $72,102 | $72,102 | $72,102 | $71,264 | N/A |
| Gross Profit | $66,264 | $66,264 | $66,264 | $66,260 | N/A |
| Gross Margin | 91.9% | 91.9% | 91.9% | 93.0% | N/A |
| Operating Income | $-4,705,694 | $-3,855,592 | $-3,627,656 | $-2,744,343 | $-2,201,719 |
| Net Income | $-4,392,880 | $-3,700,683 | $-3,908,551 | $3.90M | $-3,037,517 |
| Net Margin | -6092.6% | -5132.6% | -5420.9% | 5477.9% | N/A |
| EPS | $-1.19 | $-1.20 | $-1.71 | $1.32 | $-2.35 |
Company Overview
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SILOBeat Rate
0%
Last 3 quarters
Avg Surprise
-26.8%
EPS vs Estimate
Beats / Misses
0/2
1 met exactly
Latest EPS
$-0.12
Q4 2025
EPS Surprise History
Q1 24
-80.0%
$-0.36vs$-0.20
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.12 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.19 | — | — |
Q2 2025 | May 9, 2025 | — | $-0.23 | — | — |
Q1 2025 | Mar 28, 2025 | — | $-0.41 | — | — |
Q4 2024 | Nov 12, 2024 | — | $-0.22 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-0.31 | — | — |
Q2 2024 | May 13, 2024 | — | $-0.28 | — | — |
Q1 2024 | Mar 25, 2024 | $-0.20 | $-0.36 | -80.0% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.21 | $-0.21 | 0.0% | = MET |
Q3 2023 | Aug 12, 2023 | $-0.32 | $-0.32 | -0.4% | ✗ MISS |
Q2 2023 | May 12, 2023 | — | $-0.29 | — | — |
Q1 2023 | Mar 24, 2023 | — | $-0.78 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.51 | — | — |
Q3 2022 | Aug 1, 2022 | — | $-0.41 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.31 | — | — |
Q1 2022 | Mar 28, 2022 | — | $-0.57 | — | — |
Q4 2021 | Nov 11, 2021 | — | $3.20 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-0.24 | — | — |
Q2 2021 | May 17, 2021 | — | $-0.55 | — | — |
Latest News
Silo Pharma Selects Allucent To Support Preparations And Planned Submission Of IND For Phase 1 Trial Of SPC-15 As A Therapeutic For PTSD
📈 PositiveBenzinga•Nov 17, 2025, 01:10 PM
Silo Pharma Selects The Alphaledger/Simplify Target 12% Distribution Fund As Part Of Its Real-World Asset Investment Strategy On The Solana Blockchain
📈 PositiveBenzinga•Oct 29, 2025, 12:27 PM
Silo Pharma Provides Update On Lead PTSD Candidate, SPC-15, Highlighting Safety And Toxicology Results, Ind-Enabling Studies, And Expanded Patents In The U.S., Australia, And Japan. Company Also Launched A Digital Assets Treasury In August 2025, Acquiring Bitcoin, Ethereum, Solana, And ResearchCoin
📈 PositiveBenzinga•Oct 23, 2025, 01:04 PM•Also: , ,
Silo Pharma Invests In DeSci Innovation With Purchase Of ResearchHub's Native Token Co-Founded By Coinbase CEO, Brian Armstrong
📈 PositiveBenzinga•Oct 6, 2025, 12:16 PM•Also:
Silo Pharma shares are trading lower after the company announced a $2.5M registered direct offering priced at-the-market under Nasdaq rules.
📉 NegativeBenzinga•Sep 30, 2025, 12:16 PM
Silo Pharma Announces $2.5M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
➖ NeutralBenzinga•Sep 30, 2025, 12:14 PM
Silo Pharma shares are trading higher after the company announced it signed a strategic agreement with Fireblocks to advance its crypto treasury strategy acquisition and security.
📈 PositiveBenzinga•Sep 23, 2025, 12:50 PM
EXCLUSIVE: SILO Pharmaceuticals Tells Benzinga Co. Signs Strategic Agreement With Fireblocks To Advance Crypto Treasury Strategy Acquisition And Security
📈 PositiveBenzinga•Sep 23, 2025, 12:15 PM
SILO stock has given up its prior gain. Silo Pharma shares were trading higher after the company announced initial purchases of Ethereum and Solana under its crypto treasury strategy.
➖ NeutralBenzinga•Sep 16, 2025, 12:56 PM
Silo Pharma shares are trading higher after the company announced initial purchases of Ethereum and Solana under its crypto treasury strategy.
📈 PositiveBenzinga•Sep 16, 2025, 12:17 PM
Silo Pharma Announces Initial Purchases Of Ethereum And Solana Crypto Tokens Under Its Crypto Treasury Strategy
📈 PositiveBenzinga•Sep 16, 2025, 12:16 PM
Silo Pharma Announces Japan's Patent Office Granted Patent To Co.'s Partner, Columbia University, Titled 'Prophylactic efficacy of serotonin 4 receptor agonists against stress'
📈 PositiveBenzinga•Sep 9, 2025, 01:11 PM
Silo Pharma Secures Australian Patent For PTSD Treatment SPC-15 Through Columbia University Partnership
📈 PositiveBenzinga•Sep 3, 2025, 12:25 PM
Silo Pharma Announces Peer-Reviewed Publication Of SPC-14 Preclinical Data For Alzheimer's Disease In Alzheimer's Research & Therapy; CEO Weisblum Cites Potential For Targeted Dementia Therapies
📈 PositiveBenzinga•Aug 21, 2025, 06:03 PM
Silo Pharma Announces Bioanalytical And Safety/Toxicology Results For FDA-Requested 7-Day Large Animal Safety Study Of Its Lead Asset SPC-15
➖ NeutralBenzinga•Aug 19, 2025, 12:08 PM
Silo Pharma announces pricing of $2 million public offering
➖ NeutralSeeking Alpha•May 15, 2025, 01:24 PM
Frequently Asked Questions about SILO
What is SILO's current stock price?
Silo Pharma, Inc. (SILO) is currently trading at $0.38 per share. The stock has moved -1.40% today.
What is the analyst price target for SILO?
No analyst price targets are currently available for this stock.
What sector is Silo Pharma, Inc. in?
Silo Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SILO's market cap?
Silo Pharma, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does SILO pay dividends?
No, Silo Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBDRX
Biodexa Pharmaceuticals Plc
$3.64
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CMND
Clearmind Medicine Inc.
$2.74
Mkt Cap: $0.0B
CNSP
CNS Pharmaceuticals, Inc.
$6.51
Mkt Cap: $0.0B
GRI
GRI Bio, Inc.
$0.34
Mkt Cap: $0.0B
INM
InMed Pharmaceuticals Inc.
$1.19
Mkt Cap: $0.0B
JAGX
Jaguar Health, Inc.
$1.17
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
SNGX
Soligenix, Inc.
$1.38
Mkt Cap: $0.0B
TTNP
Titan Pharmaceuticals, Inc.
$2.34
Mkt Cap: $0.0B
Explore stocks similar to SILO for comparison